Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response
Open Access
- 26 October 2010
- journal article
- viral hepatitis
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 53 (1), 14-22
- https://doi.org/10.1002/hep.24056
Abstract
Polymorphisms of the IL28B gene are highly associated with sustained virological response (SVR) in patients with chronic hepatitis C treated with peginterferon and ribavirin. Quantitation of interferon‐γ–inducible protein‐10 (IP‐10) may also differentiate antiviral response. We evaluated IP‐10 levels in pretreatment serum from 115 nonresponders and 157 sustained responders in the Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C cohort, including African American (AA) and Caucasian American (CA) patients. Mean IP‐10 was lower in sustained responders compared with nonresponders (437 ± 31 vs 704 ± 44 pg/mL, P < 0.001), both in AA and CA patients. The positive predictive value of low IP‐10 levels (600 pg/mL) was 67%. We assessed the combination of pretreatment IP‐10 levels with IL28B genotype as predictors of treatment response. The IL28B polymorphism rs12979860 was tested in 210 participants. The CC, CT, and TT genotypes were found in 30%, 49%, and 21% of patients, respectively, with corresponding SVR rates of 87%, 50%, and 39% (P < 0.0001). Serum IP‐10 levels within the IL28B genotype groups provided additional information regarding the likelihood of SVR (P < 0.0001). CT carriers with low IP‐10 had 64% SVR versus 24% with high IP‐10. Similarly, a higher SVR rate was identified for TT and CC carriers with low versus high IP‐10 (TT, 48% versus 20%; CC, 89% versus 79%). IL28B genotype and baseline IP‐10 levels were additive but independent when predicting SVR in both AA and CA patients. Conclusion: When IL28B genotype is combined with pretreatment serum IP‐10 measurement, the predictive value for discrimination between SVR and nonresponse is significantly improved, especially in non‐CC genotypes. This relationship warrants further investigation to elucidate the mechanisms of antiviral response and prospective validation. (Hepatology 2011;)This publication has 34 references indexed in Scilit:
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapyNature Genetics, 2009
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis CHepatology, 2008
- Interferon signaling and treatment outcome in chronic hepatitis CProceedings of the National Academy of Sciences of the United States of America, 2008
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseHepatology, 2007
- Changes in Gene Expression during Pegylated Interferon and Ribavirin Therapy of Chronic Hepatitis C Virus Distinguish Responders from Nonresponders to Antiviral TherapyJournal of Virology, 2007
- Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation KineticsGastroenterology, 2006
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005